Management
Professor Trevor Jones CBE - Non-Executive Chairman
Professor Trevor Jones CBE PhD DSc FKC FPS CChem FRSC MCPP FFPM has been Chairman of ReNeuron since February 1999. He recently retired as Director General of the Association of the British Pharmaceutical Industry (ABPI), the body representing the interests of some 100 national and international pharmaceutical companies. He was, until 1994, the Main Board Director responsible for Research and Development at Wellcome plc. He was responsible for the development of a number of significant new products at Wellcome, including Zovirax (anti-herpes), Retrovir (anti-HIV), Malarone (Malaria) and Lamictal (anti-epileptic). He is visiting professor, Deputy Chair of Council and Fellow of Kings College London, and is a member of the Board of Allergan Inc.
Michael Hunt - Chief Executive Officer
Michael Hunt ACA has been a director of ReNeuron since January 2001. He joined ReNeuron as Chief Financial Officer and was appointed Chief Operating Officer in September 2003 in addition to his duties as Finance Director. Prior to ReNeuron, he spent six years at Biocompatibles International plc where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc. He studied economics at University College London and qualified as a chartered accountant with Ernst and Young.
Dr John Sinden - Founder and Chief Scientific Officer
Dr John Sinden BA MA PhD has been a director of ReNeuron since October 1998. He is a scientific co-founder of ReNeuron. Prior to founding ReNeuron, he was Reader in Neurobiology of Behaviour at the Institute of Psychiatry, Kings College London. He graduated in Psychology from the University of Sydney and completed a PhD in Neuroscience from the University of Paris at the College de France. He subsequently held post-doctoral appointments at Oxford University and at the Institute of Psychiatry prior to joining the permanent staff of the Institute in 1987.
Mark Docherty - Non-Executive Director
Mark Docherty was appointed to the Board in March 2003. He is a chartered accountant and holds a BEng in Mechanical Engineering from Sheffield University. He was a founding director of Merlin Biosciences and was actively involved in the structuring and financing of many of the Merlin Fund portfolio companies. Previously, he was a Manager in the Corporate Finance Group of Arthur Andersen. Whilst there, he gained considerable experience of running and restructuring businesses as well as preparing and negotiating their sale. He is a non-executive director of four other biotechnology companies.
Dr Paul Harper - Non Executive Director
Paul Harper BSc PhD has been working closely with the ReNeuron executive, since October 2003, to develop a strategy that exploits enhanced technology platform. This has led to need to establish a development programme with minimum delay. A graduate of Leeds University(Microbiology/Virology) he pursued a career in drug discovery and development with Glaxo as Head of Antimicrobial Chemotherapy, Johnson & Johnson as Director of R&D and with Unipath. This was followed by work in a number of start-up companies and SMEs as CEO or adviser. These included, as CEO, preparing Cambridge Antibody Technology for flotation on the LSE and founding Provensis Ltd to develop a drug device product.
Dr Kenny Pollock - Head of Cell Biology
Kenny Pollock BSc PhD joined ReNeuron in September 2001 as Head of Molecular Pharmacology. In 2002 he took over management of the Cell Biology group and joined the Management Committee in January 2004. As a graduate and post-graduate of Glasgow University (Department of Pharmacology), his core research interests for the last twenty years have been in cell signalling and cell biology. Following post-doctoral posts at the University of Cambridge and with AstraZeneca, he worked for eleven years in drug discovery research with Aventis. Prior to joining ReNeuron, he worked as a project manager with Incyte Genomics developing pharmacogenomics databases.
Dr Erik Miljan - Head of Stem Cell Discovery
Dr Miljan BSc PhD carried out his graduate studies at the University of Western Ontario, Canada, and completed his post-graduate studies at the University of Hong Kong, with a research focus on protein and glycolipid biochemistry of signal transduction. He completed a post-doctoral fellowship position at the Children's Brain Tumor Research Institute, Children's Memorial Hospital, Chicago. He joined ReNeuron in August 2002 to study signal transduction into stem cells, and now manages early stage cell biology to proof-of-concept as well as external discovery science collaborations.
Dr Paul Stroemer - Head of Pre-clinical Research
Dr Stroemer BSc PhD joined ReNeuron in September 1998 as a researcher and since 2004 has been responsible for managing both in-house and contracted pre-clinical development programs. He completed a Ph.D. at the University of Texas Medical Branch in Galveston, developing pharmacotherapies in the promotion of behavioural recovery and anatomical plasticity after stroke. Prior to joining ReNeuron, he undertook post-doctoral research at the University of Manchester examining the neuroprotective effects of reducing inflammatory responses in the brain after stroke. He now manages both internal and external pre-clinical projects.
Professor Jack Price - Principal Scientific Consultant
Jack Price BA PhD is Professor of Developmental eurobiology and Director of the Centre for the Cellular Basis of Behaviour at the Institute of Psychiatry, King's College London. He obtained a PhD in Neuroscience from University College London before a period of post-doctoral research at the Massachusetts Institute of Technology. He then directed a research group at the National Institute for Medical Research, Mill Hill. He moved to SmithKline Beecham Pharmaceuticals in 1994, where he became Director for Molecular Neurobiology. Since 1998, he has been on the permanent staff of the Institute of Psychiatry and a consultant to ReNeuron.
Top of page